Neoplasms – Chronic Lymphocytic Leukemia
The 3rd Medical Department for Hematology and Oncology at Hanusch Krankenhaus Der Wiener Gebietskrankenkasse focuses on innovative treatments for treatment‑naive chronic lymphocytic leukemia. Ongoing research tests targeted agents such as ibrutinib and venetoclax, often combined with obinutuzumab, to improve patient outcomes.
- Efficacy comparison of continuous versus fixed‑duration regimens
- Assessment of progression‑free survival as a primary endpoint
- Exploration of combination therapies involving venetoclax, obinutuzumab, and ibrutinib
With two active studies and a team of 21 investigators, the site in Vienna is contributing to the European landscape of neoplasm research, aiming to establish safer and more effective first‑line options for patients.
